Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

Cerebain Biotech Relocates Headquarters To Costa Mesa, California

05/10/2016
Cerebain Biotech, a medical device manufacturer, is relocating its corporate headquarters from Dallas, Texas to the heart of Orange County in Costa Mesa, California.

The development-stage medical device company focuses on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease.

According to company officials, “The decision to relocate was driven by the Company’s plan to seek FDA approval for its medical device for the treatment of Alzheimer’s and Dementia.”

“This move allows us to take advantage of Southern California's strong talent pool and cost-effective environment to continue to build our novel, high-value medical device,” said Eric Clemons, President/CEO of Cerebain.

“We want to be at the center of an ecosystem that shares our aspirations. Southern California attracts a diverse, technologically-fluent workforce focused on solving challenges for the world. We are excited to bring our headquarters to this dynamic and creative area,” he explained.

Cerebain Biotech has been considering the composition and location of its headquarters for more than a year, company officials said. The Company began its formal review in July 2015, with a list of a number of potential locations. Costa Mesa was selected after a careful evaluation of its location in Southern California, the business ecosystem, talent, long-term costs, quality of life for employees, connections with the world and proximity to other important company assets.

Exclusive Research